Smac induces cytochrome c release and apoptosis independently from Bax/Bcl-xL in a strictly caspase-3-dependent manner in human carcinoma cells

Oncogene

Volumn 23, Issue 26, 2004, Pages 4523-4535

  Hasenjäger, Anne ^a   Gillissen, Bernhard ^a   Müller, Antje ^a   Normand, Guillaume ^a   Hemmati, Philipp G ^a   Schuler, Martin ^b   Dörken, Bernd ^a   Daniel, Peter T ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Apoptosis; Bax; Bcl xL; Caspase 3; Caspase 9; Smac

Indexed keywords

ADENOVIRUS VECTOR; CASPASE 3; CYTOCHROME C; PROTEIN BAX; PROTEIN BCL XL; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; BAX PROTEIN, HUMAN; BCL2L1 PROTEIN, HUMAN; BENZOYLCARBONYL ASPARTYL GLUTAMYL VALYL ASPARTYL FLUOROMETHYL KETONE; BENZOYLCARBONYL-ASPARTYL-GLUTAMYL-VALYL-ASPARTYL-FLUOROMETHYL KETONE; BENZYLOXYCARBONYL LEUCYL GLUTAMYL HISTIDYL ASPARTIC ACID FLUOROMETHYL KETONE; BENZYLOXYCARBONYL-LEUCYL-GLUTAMYL-HISTIDYL-ASPARTIC ACID FLUOROMETHYL KETONE; CARRIER PROTEIN; CASP3 PROTEIN, HUMAN; CASP9 PROTEIN, HUMAN; CASPASE; CASPASE 9; CYSTEINE PROTEINASE INHIBITOR; DIABLO PROTEIN, HUMAN; MITOCHONDRIAL PROTEIN; OLIGOPEPTIDE; ONCOPROTEIN; PROTEIN BCL 2; PROTEIN BCL X; SIGNAL PEPTIDE;

APOPTOSIS; ARTICLE; BREAST ADENOCARCINOMA; CARCINOMA CELL; CONTROLLED STUDY; FEEDBACK SYSTEM; HUMAN; HUMAN CELL; MEMBRANE PERMEABILITY; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; MITOCHONDRION; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; TUMOR CELL; ADENOVIRUS; BREAST TUMOR; CARCINOMA; CELL CULTURE; DRUG ANTAGONISM; ENZYME ACTIVATION; GENETICS; METABOLISM; MUTATION; PATHOLOGY; PHYSIOLOGY; PROTEIN PROCESSING;

ADENOVIRIDAE; MINK CELL FOCUS-FORMING VIRUS;

ADENOVIRIDAE; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; BREAST NEOPLASMS; CARCINOMA; CARRIER PROTEINS; CASPASE 3; CASPASE 9; CASPASES; CYSTEINE PROTEINASE INHIBITORS; CYTOCHROMES C; ENZYME ACTIVATION; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MITOCHONDRIAL PROTEINS; MUTATION; OLIGOPEPTIDES; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR CELLS, CULTURED;

EID: 3042679658     PISSN: 09509232     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.onc.1207594     Document Type: Article

References (37)

1. Anderson RD, Haskell RE, Xia H, Roessler BJ and Davidson BL. (2000). Gene Therapy, 7, 1034-1038.
2. Bosanquet AG, Sturm I, Wieder T, Essmann F, Bosanquet MI, Head DJ, Dörken B and Daniel PT. (2002). Leukemia, 16, 1035-1044.
3. Brand K, Arnold W, Bartels T, Lieber A, Kay MA, Strauss M and Dörken B. (1997). Cancer Gene Ther., 4, 9-16.
4. Chai J, Du C, Wu JW, Kyin S, Wang X and Shi Y. (2000). Nature, 406, 855-862.
5. Cosset FL, Takeuchi Y, Battini JL, Weiss RA and Collins MK. (1995). J. Virol., 69, 7430-7436.
6. Daniel PT, Sturm I, Ritschel S, Friedrich K, Dörken B, Bendzko P and Hillebrand T. (1999). Anal. Biochem., 266, 110-115.
7. Du C, Fang M, Li Y, Li L and Wang X. (2000). Cell, 102, 33-42.
8. Ekert PG, Silke J, Hawkins CJ, Verhagen AM and Vaux DL. (2001). J. Cell Biol., 152, 483-490.
9. Friedrich K, Wieder T, von Haefen C, Radetzki S, Schulze-Osthoff K, Jänicke R, Dörken B and Daniel PT. (2001). Oncogene, 20, 2749-2760.
10. Fulda S, Wick W, Weller M and Debatin KM. (2002). Nat. Med., 8, 808-815.
11. Gillissen B, Essmann F, Graupner V, Stärck L, Radetzki S, Dörken B, Schulze-Osthoff K and Daniel PT. (2003). EMBO J., 22, 3580-3590.
12. Gossen M and Bujard H. (1992). Proc. Natl. Acad. Sci. USA, 89, 5547-5551.
13. Güner D, Sturm I, Hemmati PG, Hermann S, Hauptmann S, Wurm R, Budach V, Dörken B, Lorenz M and Daniel PT. (2003). Int. J. Cancer, 103, 445-454.
14. Guo F, Nimmanapalli R, Paranawithana S, Wittman S, Griffin D, Bali P, O'Bryan E, Fumero C, Wang HG and Bhalla K. (2002). Blood, 99, 3419-3426.
15. Hemmati PG, Gillissen B, von Haefen C, Wendt J, Stärck L, Güner D, Dörken B and Daniel PT. (2002). Oncogene, 21, 3149-3161.
16. Jänicke RU, Sprengart ML, Wati MR and Porter AG. (1998). J. Biol. Chem., 273, 9357-9360.
17. Li LY, Luo X and Wang X. (2001). Nature, 412, 95-99.
18. Lorenzo HK, Susin SA, Penninger J and Kroemer G. (1999). Cell Death Differ., 6, 516-524.
19. Martinou JC and Green DR. (2001). Nat. Rev. Mol. Cell Biol., 2, 63-67.
20. Mrozek A, Petrowsky H, Sturm I, Krauss J, Hermann S, Hauptmann S, Lorenz M and Daniel P. (2003). Cell Death Differ., in press.
21. Okada H, Suh WK, Jin J, Woo M, Du C, Elia A, Duncan GS, Wakeham A, Itie A, Lowe SW, Wang X and Mak TW. (2002). Mol. Cell Biol., 22, 3509-3517.
22. Prokop A, Wieder T, Sturm I, Essmann F, Seeger K, Wuchter C, Ludwig W-D, Henze G, Dörken B and Daniel PT. (2000). Leukemia, 14, 1606-1613.
23. Radetzki S, Könne CH, von Haefen C, Gillissen B, Sturm I, Dörken B and Daniel PT. (2002). Oncogene, 21, 227-238.
24. Raisova M, Hossini A, Eberle J, Riebeling C, Wieder T, Sturm I, Daniel PT, Orfanos CE and Geilen CC. (2001). J. Invest. Dermatol., 177, 333-340.
25. Rau B, Sturm I, Lage H, Berger S, Schneider U, Hauptmann S, Wust P, Riess H, Schlag PM, Dörken B and Daniel PT. (2003). J. Clin. Oncol., in press.
26. Roberts DL, Merrison W, MacFarlane M and Cohen GM. (2001). J. Cell Biol., 153, 221-228.
27. Schelwies K, Sturm I, Grabowski P, Scherübl H, Schindler I, Hermann S, Stein H, Buhr HJ, Riecken EO, Zeitz M, Dörken B and Daniel PT. (2002). Int. J. Cancer, 99, 589-596.
28. Slee EA, Keogh SA and Martin SJ. (2000). Cell Death Differ., 7, 556-565.
29. Sturm I, Bosanquet AG, Hermann S, Güner D, Dörken B and Daniel PT. (2003). Cell Death Differ., 10, 477-484.
30. Sturm I, Petrowsky H, Volz R, Lorenz M, Radetzki S, Hillebrand T, Wolff G, Hauptmann S, Dörken B and Daniel PT. (2001). J. Clin. Oncol., 19, 2272-2281.
31. Suzuki Y, Imai Y, Nakayama H, Takahashi K, Takio K and Takahashi R. (2001). Mol. Cell, 8, 613-621.
32. van Loo G, Saelens X, van Gurp M, MacFarlane M, Martin SJ and Vandenabeele P. (2002). Cell Death Differ., 9, 1031-1042.
33. Verhagen AM, Silke J, Ekert PG, Pakusch M, Kaufmann H, Connolly LM, Day CL, Tikoo A, Burke R, Wrobel C, Moritz RL, Simpson RJ and Vaux DL. (2002). J. Biol. Chem., 277, 445-454.
34. von Haefen C, Wieder T, Essmann F, Schulze-Osthoff K, Dörken B and Daniel PT. (2003). Oncogene, 22, 2236-2247.
35. von Haefen C, Wieder T, Gillissen B, Stärck L, Graupner V, Dörken B and Daniel PT. (2002). Oncogene, 21, 4009-4019.
36. Wu G, Chai J, Suber TL, Wu JW, Du C, Wang X and Shi Y. (2000). Nature, 408, 1008-1012.
37. Zhang L, Yu J, Park BH, Kinzler KW and Vogelstein B. (2000). Science, 290, 989-992.